UK markets close in 28 minutes

Sangamo Therapeutics, Inc. (GBY.F)

Frankfurt - Frankfurt Delayed price. Currency in EUR
Add to watchlist
0.3882+0.0164 (+4.41%)
As of 09:05AM CEST. Market open.
Currency in EUR

Valuation measures4

Market cap (intra-day) 86.35M
Enterprise value 64.36M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)3.77
Price/book (mrq)1.46
Enterprise value/revenue 3.77
Enterprise value/EBITDA -0.96

Trading information

Stock price history

Beta (5Y monthly) 1.35
52-week change 3-63.62%
S&P500 52-week change 324.96%
52-week high 31.4800
52-week low 30.2388
50-day moving average 30.4640
200-day moving average 30.5087

Share statistics

Avg vol (3-month) 3347
Avg vol (10-day) 3450
Shares outstanding 5207.51M
Implied shares outstanding 6236.13M
Float 8170.94M
% held by insiders 17.73%
% held by institutions 151.18%
Shares short 4N/A
Short ratio 4N/A
Short % of float 4N/A
Short % of shares outstanding 4N/A
Shares short (prior month ) 4N/A

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Currency in USD.

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Mar 2024

Profitability

Profit margin 0.00%
Operating margin (ttm)-9,621.00%

Management effectiveness

Return on assets (ttm)-49.47%
Return on equity (ttm)-167.24%

Income statement

Revenue (ttm)18.76M
Revenue per share (ttm)0.11
Quarterly revenue growth (yoy)-99.70%
Gross profit (ttm)N/A
EBITDA -212.39M
Net income avi to common (ttm)-328.05M
Diluted EPS (ttm)-1.7500
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)54.42M
Total cash per share (mrq)0.26
Total debt (mrq)30.82M
Total debt/equity (mrq)54.35%
Current ratio (mrq)1.71
Book value per share (mrq)0.28

Cash flow statement

Operating cash flow (ttm)-207.2M
Levered free cash flow (ttm)-120.99M